Commonly Integrated Epigenetic Modifications of Differentially Expressed Genes Lead to Adaptive Resistance in Cancer

References

• Dagogo-Jack I , ShawAT. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol.15(2), 81–94 (2018).
   PubMed Web of Science ®Google Scholar
• Holohan C , Van SchaeybroeckS , LongleyDB , JohnstonPG. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer13(10), 714–726 (2013).
   PubMed Web of Science ®Google Scholar
• Trumpp A , WiestlerOD. Mechanisms of disease: cancer stem cells – targeting the evil twin. Nat. Clin. Practice Oncol.5(6), 337–347 (2008).
   PubMedGoogle Scholar
• Dean M , FojoT , BatesS. Tumour stem cells and drug resistance. Nat. Rev. Cancer5(4), 275–284 (2005).
   PubMed Web of Science ®Google Scholar
• Glasspool RM , TeodoridisJM , BrownR. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br. J. Cancer94(8), 1087–1092 (2006).
   PubMed Web of Science ®Google Scholar
• Easwaran H , TsaiHC , BaylinSB. Cancer epigenetics: tumour heterogeneity, plasticity of stem-like states, and drug resistance. Mol. Cell54(5), 716–727 (2014).
   PubMed Web of Science ®Google Scholar
• Zeller C , DaiW , SteeleNLet al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene31(42), 4567–4576 (2012).
   PubMed Web of Science ®Google Scholar
• Sharma SV , LeeDY , LiBet al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell141(1), 69–80 (2010).
   PubMed Web of Science ®Google Scholar
• Roesch A , Fukunaga-KalabisM , SchmidtECet al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell141(4), 583–594 (2010).
   PubMed Web of Science ®Google Scholar
• Wang W , LimKG , FengMet al. KDM6B counteracts EZH2-mediated suppression of IGFBP5 to confer resistance to PI3K/AKT inhibitor treatment in breast cancer. Mol. Cancer Therap.17(9), 1973–1983 (2018).
   PubMed Web of Science ®Google Scholar
• Guler GD , TindellCA , PittiRet al. Repression of stress-induced LINE-1 expression protects cancer cell subpopulations from lethal drug exposure. Cancer Cell32(2), 221–237 (2017).
   PubMed Web of Science ®Google Scholar
• Ravindran Menon D , DasS , KreplerCet al. A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene34(34), 4448–4459 (2015).
   PubMed Web of Science ®Google Scholar
• Emran AA , MarzeseDM , MenonDRet al. Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget9(9), 8206–8222 (2018).
   PubMedGoogle Scholar
• Roulois D , LooYau H , SinghaniaRet al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell162(5), 961–973 (2015).
   PubMed Web of Science ®Google Scholar
• Liu M , OhtaniH , ZhouWet al. Vitamin C increases viral mimicry induced by 5-aza-2´-deoxycytidine. Proc. Natl Acad. Sci. USA113(37), 10238–10244 (2016).
   PubMed Web of Science ®Google Scholar
• Schubeler D , MacalpineDM , ScalzoDet al. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Development18(11), 1263–1271 (2004).
   PubMed Web of Science ®Google Scholar
• Li H , RauchT , ChenZX , SzaboPE , RiggsAD , PfeiferGP. The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells. J. Biological Chem.281(28), 19489–19500 (2006).
   PubMed Web of Science ®Google Scholar
• Leung D , DuT , WagnerUet al. Regulation of DNA methylation turnover at LTR retrotransposons and imprinted loci by the histone methyltransferase Setdb1. Proc. Natl Acad. Sci. USA111(18), 6690–6695 (2014).
   PubMed Web of Science ®Google Scholar
• Sharma B , JoshiS , SassanoAet al. Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses. J. Biol. Chem.287(50), 42352–42360 (2012).
   PubMed Web of Science ®Google Scholar
• Goltz D , GevenslebenH , VogtTJet al. CTLA4 methylation predicts response to anti–PD-1 and anti–CTLA-4 immunotherapy in melanoma patients. JCI. Insight3(13), pii: 96793 (2018).
   Web of Science ®Google Scholar
• Wang J , DingN , LiYet al. Insulin-like growth factor binding protein 5 (IGFBP5) functions as a tumor suppressor in human melanoma cells. Oncotarget6(24), 20636–20649 (2015).
   PubMedGoogle Scholar
• Wang J , ThompsonB , RenC , IttmannM , Kwabi-AddoB. Sprouty4, a suppressor of tumor cell motility, is down-regulated by DNA methylation in human prostate cancer. Prostate66(6), 613–624 (2006).
   PubMed Web of Science ®Google Scholar
• Hammerlindl H , SchaiderH. Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance. J. Cell Commun. Signal.12(1), 133–141 (2018).
   PubMed Web of Science ®Google Scholar
• Khodarev NN , BeckettM , LabayE , DargaT , RoizmanB , WeichselbaumRR. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc. Natl Acad. Sci. USA101(6), 1714–1719 (2004).
   PubMed Web of Science ®Google Scholar
• Weichselbaum RR , IshwaranH , YoonTet al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl Acad. Sci. USA105(47), 18490–18495 (2008).
   PubMed Web of Science ®Google Scholar
• Khodarev NN , MinnAJ , EfimovaEVet al. Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Res.67(19), 9214–9220 (2007).
   PubMed Web of Science ®Google Scholar
• Benci JL , XuB , QiuYet al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell167(6), 1540–1554 (2016).
   PubMed Web of Science ®Google Scholar
• Tahara E Jr , TaharaH , KannoMet al. G1P3, an interferon inducible gene 6–16, is expressed in gastric cancers and inhibits mitochondrial-mediated apoptosis in gastric cancer cell line TMK-1 cell. Cancer Immunol. Immunother.54(8), 729–740 (2005).
   PubMed Web of Science ®Google Scholar
• Yen Ai-Hsin , ChenY-C , VijayaKumar Pidugu , LiuChung-Ji , LeeTe-Chang. Association of interferon-induced protein with tetratricopeptide repeats 1 and 3 expression with regional metastasis and drug resistance in oral squamous cell carcinoma. Cancer Res.74(19), 40 (2014).
   Web of Science ®Google Scholar
• Fu TY , WuCN , SieHCet al. Subsite-specific association of DEAD box RNA helicase DDX60 with the development and prognosis of oral squamous cell carcinoma. Oncotarget7(51), 85097–85108 (2016).
   PubMedGoogle Scholar
• Januchowski R , SterzynskaK , ZawieruchaPet al. Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines. Oncotarget8(30), 49944–49958 (2017).
   PubMedGoogle Scholar
• Wilmott JS , HayduLE , MenziesAMet al. Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. J. Immunol.192(5), 2505–2513 (2014).
   PubMed Web of Science ®Google Scholar
• Wagner S , VlachogiannisG , DeHaven Brandon Aet al. Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. Oncogene38(10), 1717–1733 (2018).
   PubMed Web of Science ®Google Scholar
• Liu D , LiuX , XingM. Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells. Cell Cycle (Georgetown, Tex.)13(2), 208–219 (2014).
   PubMed Web of Science ®Google Scholar
• Yu Q , KatlinskayaYV , CarboneCJet al. DNA-damage-induced type I interferon promotes senescence and inhibits stem cell function. Cell Reports11(5), 785–797 (2015).
   PubMed Web of Science ®Google Scholar
• Efimova EV , LiangH , PitrodaSPet al. Radioresistance of Stat1 over-expressing tumor cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signaling. Internat. J. Radiation Biol.85(5), 421–431 (2009).
   PubMed Web of Science ®Google Scholar
• Tiffen JC , GallagherSJ , TsengHY , FilippFV , FazekasDe St Groth B , HerseyP. EZH2 as a mediator of treatment resistance in melanoma. Pigment Cell Melanoma Res.29(5), 500–507 (2016).
   PubMed Web of Science ®Google Scholar
• Ohgushi M , KurokiS , FukamachiHet al. Transforming growth factor beta-dependent sequential activation of Smad, Bim, and caspase-9 mediates physiological apoptosis in gastric epithelial cells. Mol. Cell Biol.25(22), 10017–10028 (2005).
   PubMed Web of Science ®Google Scholar
• Go C , LiP , WangXJ. Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis. Cancer Res.59(12), 2861–2868 (1999).
   PubMed Web of Science ®Google Scholar
• Lacerte A , KorahJ , RoyM , YangXJ , LemayS , LebrunJJ. Transforming growth factor-beta inhibits telomerase through SMAD3 and E2F transcription factors. Cell Signal.20(1), 50–59 (2008).
   PubMed Web of Science ®Google Scholar
• Rakoff-Nahoum S , MedzhitovR. Toll-like receptors and cancer. Nat. Rev. Cancer9(1), 57–63 (2009).
   PubMed Web of Science ®Google Scholar
• Salaun B , CosteI , RissoanMC , LebecqueSJ , RennoT. TLR3 can directly trigger apoptosis in human cancer cells. J. Immunol.176(8), 4894–4901 (2006).
   PubMed Web of Science ®Google Scholar
• Sedger LM , McDermottMF. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants – past, present and future. Cytokine Growth Factor Rev.25(4), 453–472 (2014).
   PubMed Web of Science ®Google Scholar
• Carswell EA , OldLJ , KasselRL , GreenS , FioreN , WilliamsonB. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA72(9), 3666–3670 (1975).
   PubMed Web of Science ®Google Scholar
• Mason JM , MorrisonDJ , BassonMA , LichtJD. Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. Trends Cell. Biol.16(1), 45–54 (2006).
   PubMed Web of Science ®Google Scholar
• Tennis MA , Van ScoykMM , FreemanSV , VandervestKM , NemenoffRA , WinnRA. Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial–mesenchymal transition, and is regulated by Wnt7A through PPARgamma in non-small cell lung cancer. Mol. Cancer Res.8(6), 833–843 (2010).
   PubMed Web of Science ®Google Scholar
• Vanas V , MuhlbacherE , KralR , Sutterluty-FallH. Sprouty4 interferes with cell proliferation and migration of breast cancer-derived cell lines. Tumour Biol.35(5), 4447–4456 (2014).
   PubMedGoogle Scholar
• Jing H , LiawL , FrieselR , VaryC , HuaS , YangX. Suppression of Spry4 enhances cancer stem cell properties of human MDA-MB-231 breast carcinoma cells. Cancer Cell Int.16, 19 (2016).
   PubMed Web of Science ®Google Scholar
• Ding M , BruickRK , YuY. Secreted IGFBP5 mediates mTORC1-dependent feedback inhibition of IGF-1 signaling. Nat. Cell Biol.18(3), 319–327 (2016).
   PubMed Web of Science ®Google Scholar
• Gullu G , KarabulutS , AkkiprikM. Functional roles and clinical values of insulin-like growth factor-binding protein-5 in different types of cancers. Chinese J. Cancer31(6), 266–280 (2012).
   PubMedGoogle Scholar
• Akkiprik M , HuL , SahinA , HaoX , ZhangW. The subcellular localization of IGFBP5 affects its cell growth and migration functions in breast cancer. BMC Cancer9, 103 (2009).
   PubMed Web of Science ®Google Scholar
• Luther GA , LamplotJ , ChenXet al. IGFBP5 domains exert distinct inhibitory effects on the tumorigenicity and metastasis of human osteosarcoma. Cancer Lett.336(1), 222–230 (2013).
   PubMed Web of Science ®Google Scholar